See more : Ocumetics Technology Corp. (OTC.V) Income Statement Analysis – Financial Results
Complete financial analysis of Newron Pharmaceuticals S.p.A. (NWRN.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Newron Pharmaceuticals S.p.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Saga Furs Oyj (SAGCV.HE) Income Statement Analysis – Financial Results
- Z-Work Acquisition Corp. (ZWRKW) Income Statement Analysis – Financial Results
- Grodno Spólka Akcyjna (GRN.WA) Income Statement Analysis – Financial Results
- GiG Works Inc. (2375.T) Income Statement Analysis – Financial Results
- PPB Group Berhad (4065.KL) Income Statement Analysis – Financial Results
Newron Pharmaceuticals S.p.A. (NWRN.SW)
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.06M | 6.09M | 5.76M | 5.26M | 7.04M | 4.03M | 13.43M | 6.73M | 2.38M | 1.56M | 3.54M | 8.92M | 280.00K | 806.00K | 2.54M | 3.93M | 4.02M | 1.19M | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 295.00K | 1.43M | 1.37M | 0.00 | 2.63M | 1.26M | 477.00K | 269.00K | 28.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 9.06M | 6.09M | 5.76M | 4.96M | 5.61M | 2.65M | 13.43M | 4.09M | 1.12M | 1.08M | 3.27M | 8.90M | 280.00K | 806.00K | 2.54M | 3.93M | 4.02M | 1.19M | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 94.39% | 79.75% | 65.91% | 100.00% | 60.84% | 46.97% | 69.36% | 92.40% | 99.69% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 13.15M | 12.05M | 10.76M | 16.33M | 22.46M | 15.82M | 13.38M | 19.24M | 16.57M | 14.47M | 4.54M | 3.53M | 3.82M | 15.92M | 18.54M | 12.88M | 8.20M | 11.49M | 10.60M |
| General & Administrative | 3.98M | 7.15M | 7.24M | 8.06M | 9.78M | 8.44M | 8.08M | 8.82M | 8.13M | 6.57M | 3.79M | 4.15M | 6.90M | 6.45M | 8.47M | 9.26M | 9.45M | 6.62M | 4.54M |
| Selling & Marketing | 80.00K | 81.00K | 38.00K | 331.00K | 634.00K | 406.00K | 708.00K | 513.00K | 53.00K | 53.00K | 15.00K | 62.00K | 51.00K | 73.00K | 86.00K | 115.00K | 131.00K | 0.00 | 0.00 |
| SG&A | 4.06M | 7.39M | 7.39M | 8.47M | 10.50M | 9.17M | 9.50M | 10.01M | 8.58M | 6.95M | 3.81M | 4.21M | 6.95M | 6.52M | 8.55M | 9.37M | 9.58M | 6.62M | 4.54M |
| Other Expenses | 3.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.97M | 3.87M | -10.00K | 0.00 | 0.00 | 0.00 | 0.00 | -164.00K | -67.00K |
| Operating Expenses | 20.69M | 19.68M | 17.78M | 22.70M | 26.82M | 19.12M | 18.85M | 22.04M | 27.49M | 12.39M | 11.32M | 11.62M | 6.76M | 22.45M | 27.10M | 22.25M | 17.78M | 17.94M | 15.08M |
| Cost & Expenses | 20.69M | 19.68M | 17.78M | 22.70M | 26.82M | 19.12M | 18.85M | 22.04M | 27.49M | 12.39M | 11.32M | 11.62M | 6.76M | 22.45M | 27.10M | 22.25M | 17.78M | 17.94M | 15.08M |
| Interest Income | 179.00K | 3.89M | 2.86M | 2.18M | 381.00K | 76.00K | 119.00K | 106.00K | 123.00K | 107.00K | 1.00K | 84.00K | 72.00K | 31.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.17M | 3.95M | 2.92M | 2.24M | 572.00K | 56.00K | 85.00K | 132.00K | 17.00K | 0.00 | 0.00 | 16.00K | 6.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | -157.00K |
| Depreciation & Amortization | 201.00K | 202.00K | 209.00K | 219.00K | 206.00K | 47.00K | 48.00K | 33.00K | 71.00K | 33.00K | 39.00K | 63.00K | 88.00K | 149.00K | 524.00K | 271.00K | 213.00K | 0.00 | 0.00 |
| EBITDA | -11.83M | -13.32M | -12.31M | -17.99M | -20.85M | -14.79M | -4.05M | -15.29M | -17.60M | -11.18M | -7.74M | -2.63M | -6.34M | -21.49M | -24.03M | -18.05M | -13.47M | -16.73M | -15.08M |
| EBITDA Ratio | -130.63% | -217.67% | -213.64% | -342.22% | -296.21% | -367.35% | -30.15% | -227.36% | -739.66% | -581.70% | -218.62% | -27.10% | -2,261.43% | -2,666.38% | -945.40% | -458.89% | -336.43% | -1,406.55% | 0.00% |
| Operating Income | -11.63M | -13.30M | -12.36M | -18.07M | -20.90M | -14.98M | -4.10M | -15.33M | -17.68M | -9.09M | -7.78M | -2.70M | -6.48M | -21.64M | -24.56M | -18.32M | -13.68M | -16.75M | -15.08M |
| Operating Income Ratio | -128.40% | -218.28% | -214.46% | -343.59% | -296.95% | -372.12% | -30.50% | -227.85% | -742.65% | -583.82% | -219.72% | -30.22% | -2,315.00% | -2,684.86% | -966.01% | -465.78% | -339.99% | -1,406.55% | 0.00% |
| Total Other Income/Expenses | -4.57M | -4.17M | -2.53M | -1.55M | 737.00K | -41.00K | -955.00K | 121.00K | -583.00K | 492.00K | 63.00K | 200.00K | 45.00K | -33.00K | 205.00K | 1.96M | 2.59M | 351.00K | 157.00K |
| Income Before Tax | -16.20M | -17.47M | -14.88M | -19.62M | -20.16M | -15.02M | -5.30M | -15.20M | -24.98M | -10.72M | -7.71M | -2.50M | -6.44M | -21.67M | -24.35M | -16.36M | -11.09M | -16.40M | -14.92M |
| Income Before Tax Ratio | -178.87% | -286.71% | -258.31% | -373.11% | -286.47% | -373.14% | -39.48% | -226.05% | -1,049.71% | -688.70% | -217.94% | -27.98% | -2,298.93% | -2,688.96% | -957.95% | -415.87% | -275.55% | -1,377.08% | 0.00% |
| Income Tax Expense | 24.00K | 21.00K | 17.00K | 1.38M | 45.00K | 16.00K | 19.00K | 33.00K | 2.17M | 628.00K | -615.00K | -122.00K | 8.00K | -1.13M | -870.00K | 8.00K | 1.00K | -351.00K | -157.00K |
| Net Income | -16.22M | -17.49M | -14.90M | -21.00M | -20.21M | -15.04M | -5.28M | -15.24M | -22.82M | -10.10M | -7.10M | -2.38M | -6.45M | -20.55M | -23.48M | -16.36M | -11.09M | -16.40M | -14.92M |
| Net Income Ratio | -179.13% | -287.05% | -258.61% | -399.35% | -287.11% | -373.54% | -39.34% | -226.54% | -958.66% | -648.36% | -200.57% | -26.61% | -2,301.79% | -2,549.01% | -923.72% | -416.07% | -275.57% | -1,377.08% | 0.00% |
| EPS | -0.91 | -0.98 | -0.84 | -1.18 | -1.13 | -0.84 | -0.32 | -1.04 | -1.66 | -0.80 | -0.62 | -0.29 | -0.89 | -3.11 | -3.86 | -2.74 | -1.90 | -4.33 | -5.29 |
| EPS Diluted | -0.91 | -0.98 | -0.84 | -1.18 | -1.13 | -0.84 | -0.32 | -1.04 | -1.66 | -0.80 | -0.62 | -0.29 | -0.89 | -3.11 | -3.86 | -2.74 | -1.90 | -4.33 | -5.29 |
| Weighted Avg Shares Out | 17.85M | 17.85M | 17.85M | 17.85M | 17.85M | 17.84M | 16.30M | 14.69M | 13.72M | 12.69M | 11.51M | 8.16M | 7.26M | 6.61M | 6.09M | 5.96M | 5.83M | 3.79M | 2.82M |
| Weighted Avg Shares Out (Dil) | 17.85M | 17.85M | 17.85M | 17.85M | 17.85M | 17.84M | 16.30M | 14.69M | 13.72M | 12.69M | 11.51M | 8.16M | 7.26M | 6.61M | 6.09M | 5.96M | 5.83M | 3.79M | 2.82M |
Source: https://incomestatements.info
Category: Stock Reports